CVRFX
Price
$13.92
Change
-$0.38 (-2.66%)
Updated
Dec 18 closing price
RMFCX
Price
$54.22
Change
-$1.42 (-2.55%)
Updated
Dec 18 closing price
Ad is loading...

CVRFX vs RMFCX

Header iconCVRFX vs RMFCX Comparison
Open Charts CVRFX vs RMFCXBanner chart's image
Pioneer Disciplined Value R
Price$13.92
Change-$0.38 (-2.66%)
VolumeN/A
CapitalizationN/A
American Funds American Mutual R3
Price$54.22
Change-$1.42 (-2.55%)
VolumeN/A
CapitalizationN/A
CVRFX vs RMFCX Comparison Chart
Loading...
View a ticker or compare two or three
VS
CVRFX vs. RMFCX commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVRFX is a Hold and RMFCX is a Buy.

FUNDAMENTALS
Fundamentals
RMFCX has more cash in the bank: 98.7B vs. CVRFX (401M). RMFCX pays higher dividends than CVRFX: RMFCX (1.69) vs CVRFX (1.03). CVRFX was incepted earlier than RMFCX: CVRFX (19 years) vs RMFCX (23 years). CVRFX is a more actively managed with annual turnover of: 143.00 vs. RMFCX (25.00). CVRFX has a lower initial minimum investment than RMFCX: CVRFX (0) vs RMFCX (250). CVRFX (12.98) and RMFCX (12.63) have marching annual gain over last year. RMFCX return over 5 years is better than : 40.39 vs. CVRFX (4.91).
CVRFXRMFCXCVRFX / RMFCX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence19 years23 years-
Gain YTD11.55911.423101%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets401M98.7B0%
Annual Yield % from dividends1.031.6961%
Returns for 1 year12.9812.63103%
Returns for 3 years0.8714.166%
Returns for 5 years4.9140.3912%
Returns for 10 years-10.9061.84-18%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
REKR0.83N/A
-0.01%
Rekor Systems
CRBG29.99-0.44
-1.45%
Corebridge Financial
WHD61.48-1.46
-2.32%
Cactus
ABCL2.79-0.07
-2.45%
AbCellera Biologics
TRIB0.85-0.05
-5.67%
Trinity Biotech plc